These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 32414649)

  • 1. Research Progress on Long Non-coding RNAs and Drug Resistance of Breast Cancer.
    Zhang X; Yang H
    Clin Breast Cancer; 2020 Aug; 20(4):275-282. PubMed ID: 32414649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long non-coding RNAs engender drug resistance to different subtypes of treatments of breast cancers and may provide a "next generation" therapy option.
    Chen WT; Wu HT; Shen JX; Ye QQ; Zhang ML; Chen WJ; Liu J
    Discov Med; 2020; 29(156):27-39. PubMed ID: 32598860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long non-coding RNAs AC026904.1 and UCA1: a "one-two punch" for TGF-β-induced SNAI2 activation and epithelial-mesenchymal transition in breast cancer.
    Li GY; Wang W; Sun JY; Xin B; Zhang X; Wang T; Zhang QF; Yao LB; Han H; Fan DM; Yang AG; Jia LT; Wang L
    Theranostics; 2018; 8(10):2846-2861. PubMed ID: 29774079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNA ZEB2-AS1 promotes the proliferation, metastasis and epithelial mesenchymal transition in triple-negative breast cancer by epigenetically activating ZEB2.
    Zhang G; Li H; Sun R; Li P; Yang Z; Liu Y; Wang Z; Yang Y; Yin C
    J Cell Mol Med; 2019 May; 23(5):3271-3279. PubMed ID: 30825262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of long non-coding RNA ROR reverses resistance to Tamoxifen by inducing autophagy in breast cancer.
    Li Y; Jiang B; Zhu H; Qu X; Zhao L; Tan Y; Jiang Y; Liao M; Wu X
    Tumour Biol; 2017 Jun; 39(6):1010428317705790. PubMed ID: 28635401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer.
    Shi SJ; Wang LJ; Yu B; Li YH; Jin Y; Bai XZ
    Oncotarget; 2015 May; 6(13):11652-63. PubMed ID: 25871474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long noncoding RNA H19 acts as a miR-340-3p sponge to promote epithelial-mesenchymal transition by regulating YWHAZ expression in paclitaxel-resistant breast cancer cells.
    Yan L; Yang S; Yue CX; Wei XY; Peng W; Dong ZY; Xu HN; Chen SL; Wang WR; Chen CJ; Yang QL
    Environ Toxicol; 2020 Sep; 35(9):1015-1028. PubMed ID: 32420678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA LINP1 confers tamoxifen resistance and negatively regulated by ER signaling in breast cancer.
    Ma T; Liang Y; Li Y; Song X; Zhang N; Li X; Chen B; Zhao W; Wang L; Yang Q
    Cell Signal; 2020 Apr; 68():109536. PubMed ID: 31927036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long non-coding RNAs (LncRNA) regulated by transforming growth factor (TGF) β: LncRNA-hit-mediated TGFβ-induced epithelial to mesenchymal transition in mammary epithelia.
    Richards EJ; Zhang G; Li ZP; Permuth-Wey J; Challa S; Li Y; Kong W; Dan S; Bui MM; Coppola D; Mao WM; Sellers TA; Cheng JQ
    J Biol Chem; 2015 Mar; 290(11):6857-67. PubMed ID: 25605728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing therapeutic resistance in breast cancer: from the lncRNAs perspective.
    Peng L; Jiang J; Tang B; Nice EC; Zhang YY; Xie N
    Theranostics; 2020; 10(23):10360-10377. PubMed ID: 32929354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long noncoding RNAs as regulators of epithelial mesenchymal transition in breast cancer: A recent review.
    El-Ashmawy NE; Khedr EG; Abo-Saif MA; Hamouda SM
    Life Sci; 2024 Jan; 336():122339. PubMed ID: 38097110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA expression signatures of twist-induced epithelial-to-mesenchymal transition in MCF10A cells.
    Hu P; Yang J; Hou Y; Zhang H; Zeng Z; Zhao L; Yu T; Tang X; Tu G; Cui X; Liu M
    Cell Signal; 2014 Jan; 26(1):83-93. PubMed ID: 24113349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway.
    Lu PW; Li L; Wang F; Gu YT
    J Cell Physiol; 2019 Feb; 234(2):1904-1912. PubMed ID: 30145819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of endoplasmic reticulum stress on the autophagy, apoptosis, and chemotherapy resistance of human breast cancer cells by regulating the PI3K/AKT/mTOR signaling pathway.
    Zhong JT; Yu J; Wang HJ; Shi Y; Zhao TS; He BX; Qiao B; Feng ZW
    Tumour Biol; 2017 May; 39(5):1010428317697562. PubMed ID: 28459209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newly identified lncRNA-45 promotes breast cancer metastasis through activating the mTOR signaling pathway.
    Qiu J; Guo Y; Wang S; Ren Q; Dong Z; Gao M; Ma J; Chen S; Liu S
    Biochem Biophys Res Commun; 2023 Jan; 640():40-49. PubMed ID: 36502630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYC-binding lncRNA EPIC1 promotes AKT-mTORC1 signaling and rapamycin resistance in breast and ovarian cancer.
    Wang Y; Zhang M; Wang Z; Guo W; Yang D
    Mol Carcinog; 2020 Oct; 59(10):1188-1198. PubMed ID: 32810332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
    Brown WS; Akhand SS; Wendt MK
    Oncotarget; 2016 Dec; 7(50):83424-83436. PubMed ID: 27825137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epithelial to mesenchymal transition is associated with rapamycin resistance.
    Holder AM; Akcakanat A; Adkins F; Evans K; Chen H; Wei C; Milton DR; Li Y; Do KA; Janku F; Meric-Bernstam F
    Oncotarget; 2015 Aug; 6(23):19500-13. PubMed ID: 25944619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer.
    Li W; Zhai L; Wang H; Liu C; Zhang J; Chen W; Wei Q
    Oncotarget; 2016 May; 7(19):27778-86. PubMed ID: 27034004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA-miRNA axes in breast cancer: Novel points of interaction for strategic attack.
    Venkatesh J; Wasson MD; Brown JM; Fernando W; Marcato P
    Cancer Lett; 2021 Jul; 509():81-88. PubMed ID: 33848519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.